Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab monotherapy in moderate to severe rheumatoid arthritis
2013-004051-20Phase 4Completed
- Sponsor
- Fundación Española de Reumatología
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Fundación Española de Reumatología. Primary endpoint: Rate of patients reaching good or moderate EULAR response. Started Dec 2013; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2013-004051-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004051-20.